SIH Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

SIH Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,639	Closed	-$94.8K	–	182
2025 Q1	$94.8K	Buy	+12,639	New	+$102K	﹤0.01%	243

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SIH Partners's BCRX Position: Q2 2025 in Review

SIH Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 12,639 shares — an estimated $94.8K sold.

SIH Partners first reported a position in BCRX in Q1 2025 and held it in 1 quarter. The position peaked at $94.8K in Q1 2025. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

SIH Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 12,639 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $94.8K.
SIH Partners first reported a position in BioCryst Pharmaceuticals in Q1 2025 and held it in 1 quarter.
SIH Partners's BioCryst Pharmaceuticals position peaked at $94.8K in Q1 2025.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.